Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections
Shots:
- The companies collaborated to evaluate IMU-838 (DHODH inhibitors) + NHC (nucleoside analogues) to treat patients with viral infections including COVID-19 and Influenza
- The preclinical research showed that IMU-838 strongly synergizes with selected nucleoside analogues to inhibit SARS-CoV-2 replication in vitro. In vitro test system- IMU-838 & NHC alone showed 99.9% & 99% reduction in viral RNA at concentrations of 5μM & 100 nM
- The enrollment of the first patient in the P-II CALLIPER trial of IMU-838 for MS is expected in Sept’21 & for the P-III ENSURE program in Q4’21. Additionally- the P-II results of IMU-838 in UC is expected to be available in Q2’22
Click here | Ref: Immunic | Image: PR Newswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com